PMV Pharmaceuticals (PMVP) Forecast 2026: One Mutation, One Oral Drug, and a Re-Rating That Could Hit Fast
We recently published our article Top 10 Cancer Biotech Small-Caps That Could Shock the Market Next. This piece…
Oncolytics (ONCY) Is a $90M “Science vs. Reality” Fight—And 2026 Is When Pelareorep Has to Win
We recently published our article Top 10 Cancer Biotech Small-Caps That Could Shock the Market Next. This piece…
Nkarta (NKTX)’s Plot Twist: From Cancer Chaos to Autoimmune “Immune Reset” Hype
We recently published our article Top 10 Cancer Biotech Small-Caps That Could Shock the Market Next. This piece…
Context (CNTX)’s Glow-Up: From “Old Thesis” to T-Cell Engager Chaos (In a Good Way)
We recently published our article Top 10 Cancer Biotech Small-Caps That Could Shock the Market Next. This piece…
The $290M Cancer Biotech With Phase 3 “Proof”: Candel (CADL)’s Viral Immunotherapy Isn’t Just a Science Fair Anymore
We recently published our article Top 10 Cancer Biotech Small-Caps That Could Shock the Market Next. This piece…
Verastem (VSTM) Isn’t “Small-Cap Roulette” Anymore—It’s a Commercial Oncology Ramp With a 2026 Twist
We recently published our article Top 10 Cancer Biotech Small-Caps That Could Shock the Market Next. This piece…
The Market Cap Is Small, the Idea Is Huge: Can Allogene (ALLO) Make CAR-T as Easy as Ordering a Drug?
We recently published our article Top 10 Cancer Biotech Small-Caps That Could Shock the Market Next. This piece…
44% Real-World Response? Iovance (IOVA) Just Made “Off-the-Bench” Data the New Headline
We recently published our article Top 10 Cancer Biotech Small-Caps That Could Shock the Market Next. This piece…
Compass Therapeutics (CMPX) Has a “Survival Data” Trapdoor — And 2026 Might Be When It Opens
We recently published our article Top 10 Cancer Biotech Small-Caps That Could Shock the Market Next. This piece…
Nuvation (NUVB)’s “Quiet Launch” Isn’t Quiet Anymore: The Patient-Start Numbers That Got Biotech Watching
We recently published our article Top 10 Cancer Biotech Small-Caps That Could Shock the Market Next. This piece…
Top 10 Cancer Biotech Small-Caps That Could Shock the Market Next
In this article, we will take a look at the Top 10 Cancer Biotech Small-Caps That Could Shock…
The “No Heart Damage” Cancer Drug Angle: Is Moleculin (MBRX)’s Annamycin the Plot Twist in AML?
We recently published our article Top 5 Best Biotech Micro-Caps With Major Clinical Catalysts in 2026. This piece…
Achieve Life Sciences (ACHV) Has a June 2026 “Make-or-Break” Date—Is This the Smoking Cessation Biotech Everyone’s Early On?
We recently published our article Top 5 Best Biotech Micro-Caps With Major Clinical Catalysts in 2026. This piece…
Avalo Therapeutics (AVTX)’s Next 5 Minutes of Fame: The HS Data Drop That Could Shock Traders
We recently published our article Top 5 Best Biotech Micro-Caps With Major Clinical Catalysts in 2026. This piece…
DBV Technologies (DBVT) Didn’t Chase a Fad — It Built a Category: The Peanut Allergy Patch
We recently published our article Top 5 Best Biotech Micro-Caps With Major Clinical Catalysts in 2026. This piece…
MindMed (MNMD) Stock 101: Why This Psychedelic Biotech Isn’t Playing Small Anymore
We recently published our article Top 5 Best Biotech Micro-Caps With Major Clinical Catalysts in 2026. This piece…
Top 5 Best Biotech Micro-Caps With Major Clinical Catalysts in 2026
In this article, we will take a look at the Top 5 Best Biotech Micro-Caps With Major Clinical…
ADMA Biologics (ADMA): #1 Biotech Stock Pick for February 2026
We recently published our article Top 5 Best Biotech Stocks of February 2026. This piece looks at ADMA…